secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002697
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel names Mark Pavao Interim CCO; plans sNDA for IGALMI at-home use
-----------------------------------------------------------------------

- Mark Pavao appointed Interim Chief Commercial Officer to support potential IGALMI at-home launch.
- Company plans to submit supplemental NDA this month for FDA approval of IGALMI for at-home use.
- IGALMI targets acute agitation in bipolar disorders or schizophrenia; at-home expansion is key strategic move.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926002697/0001104659-26-002697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926002697/tm262900d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer